We are live on !
Find out more
Dmitry Balyasny Balyasny Asset Management
AUM
$80.2B
Turnover
42.78%
1-Year Est. Return
51.53%
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+51.53%
3 Year Est. Return
+149.76%
5 Year Est. Return
+199.38%
10 Year Est. Return
+875.18%
AUM
$80.2B
AUM Growth
+$3.12B
(+4%)
Cap. Flow
-$3.01B
Cap. Flow % of AUM
Cap. Flow %
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
13.57%
Holding
3,665
New
834
Increased
989
Reduced
995
Closed
734
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 36.95% |
| 2 | Technology | 12.69% |
| 3 | Industrials | 10% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Healthcare | 7.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2326
Werewolf Therapeutics
HOWL
$49.6M
| $644K | ﹤0.01% |
+1,790,089
| New | +$1.09M |
2026 Q2
0 quarters
|
|
2327
PUT
Nutrien
NTR
$33.2B
| $642K | ﹤0.01% |
+10,200
| New | +$713K |
2026 Q2
0 quarters
|
|
2328
ResMed
RMD
$32.3B
| $641K | ﹤0.01% |
3,291
+1,094
| +50% | +$227K |
2025 Q4
2 quarters
|
|
2329
Zebra Technologies
ZBRA
$17.4B
| $637K | ﹤0.01% |
2,420
-587
| -20% | -$138K |
2026 Q1
1 quarter
|
|
2330
Procept Biorobotics
PRCT
$1.12B
| $637K | ﹤0.01% |
28,201
-45,741
| -62% | -$1.15M |
2026 Q1
1 quarter
|
|
2331
Aeluma Inc
ALMU
$156M
| $637K | ﹤0.01% |
+28,834
| New | +$617K |
2026 Q2
0 quarters
|
|
2332
Trade Desk
TTD
$5.97B
| $635K | ﹤0.01% |
+35,127
| New | +$746K |
2026 Q2
0 quarters
|
|
2333
Fair Isaac
FICO
$15.7B
| $631K | ﹤0.01% |
528
+174
| +49% | +$195K |
2025 Q1
5 quarters
|
|
2334
LTC Properties
LTC
$2.42B
| $630K | ﹤0.01% |
16,388
-52,833
| -76% | -$2.01M |
2023 Q3
11 quarters
|
|
2335
Praxis Precision Medicines
PRAX
$7.87B
| $629K | ﹤0.01% |
+1,880
| New | +$595K |
2026 Q2
0 quarters
|
|
2336
TKO Group
TKO
$13.5B
| $629K | ﹤0.01% |
3,126
+1,742
| +126% | +$340K |
2024 Q4
6 quarters
|
|
2337
F5
FFIV
$18.6B
| $628K | ﹤0.01% |
1,509
+547
| +57% | +$194K |
2025 Q1
5 quarters
|
|
2338
Beyond Meat
BYND
$129M
| $626K | ﹤0.01% |
27,810
+22,022
| +380% | +$513K |
2025 Q4
2 quarters
|
|
2339
Custom Truck One Source
CTOS
$2.46B
| $625K | ﹤0.01% |
52,960
-11,049
| -17% | -$104K |
2025 Q4
2 quarters
|
|
2340
CALL
Align Technology
ALGN
$10.9B
| $624K | ﹤0.01% |
3,700
| – | – |
2025 Q4
2 quarters
|
|
2341
CALL
Southern Company
SO
$107B
| $622K | ﹤0.01% |
6,500
-28,600
| -81% | -$2.69M |
2025 Q4
2 quarters
|
|
2342
Tsakos Energy Navigation Ltd
TEN
$1.56B
| $622K | ﹤0.01% |
+17,584
| New | +$699K |
2026 Q2
0 quarters
|
|
2343
Neuphoria Therapeutics
NEUP
$16.6M
| $622K | ﹤0.01% |
142,228
+45
| +0% | +$217 |
2026 Q1
1 quarter
|
|
2344
PUT
Centrus Energy
LEU
$2.14B
| $621K | ﹤0.01% |
+3,700
| New | +$691K |
2026 Q2
0 quarters
|
|
2345
QuinStreet
QNST
$1.03B
| $618K | ﹤0.01% |
42,161
-496,045
| -92% | -$6.23M |
2025 Q4
2 quarters
|
|
2346
Eversource Energy
ES
$25.9B
| $617K | ﹤0.01% |
8,536
+2,936
| +52% | +$203K |
2025 Q3
3 quarters
|
|
2347
Fiserv Inc
FISV
$27.5B
| $616K | ﹤0.01% |
12,560
-225,559
| -95% | -$12.6M |
2025 Q4
2 quarters
|
|
2348
PPG Industries
PPG
$27.5B
| $613K | ﹤0.01% |
5,057
+14
| +0.3% | +$1.56K |
2025 Q4
2 quarters
|
|
2349
PUT
Unity
U
$17.6B
| $612K | ﹤0.01% |
+21,400
| New | +$569K |
2026 Q2
0 quarters
|
|
2350
Cellectar Biosciences
CLRB
$11.6M
| $612K | ﹤0.01% |
+220,000
| New | +$615K |
2026 Q2
0 quarters
|
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $3.01B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.